Vaccine Pharmacovigilance Experts are instrumental in ensuring the ongoing safety and efficacy of vaccines once they are distributed to the public. Their primary responsibility is to monitor, evaluate, and report on adverse events that may occur after vaccination. This includes gathering data from healthcare providers, patients, and clinical studies, which is then analyzed to identify any patterns or risks. These experts play a crucial role in detecting potential side effects that may not have been identified in clinical trials, thus safeguarding public health and maintaining the trust in immunization programs. Through their continuous monitoring, they contribute significantly to updating vaccine safety guidelines and improving the overall vaccination process.
Vaccine pharmacovigilance experts collaborate with regulatory agencies, pharmaceutical companies, and healthcare professionals to ensure that vaccines meet all safety and efficacy standards. They provide recommendations for risk management, assist in labeling and patient education, and help develop strategies for minimizing risks associated with immunizations. They are also involved in post-marketing surveillance, ensuring that any emerging safety concerns are promptly addressed. Their work ensures that vaccines remain safe and effective, benefiting populations worldwide. As vaccine deployment continues to expand globally, their expertise is vital in adapting to new challenges and ensuring the effectiveness of immunization efforts. Their role is key in maintaining public confidence, as they help ensure that vaccines are both safe and reliable for all age groups. By continuously evaluating and improving vaccine safety, they are integral to the fight against infectious diseases worldwide.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States